Comparing the current results to its competitors, T2 Biosystems Inc reported Revenue increase in the 4 quarter 2024 by 34.85 % year on year, while most of its competitors have experienced contraction in revenues by -1.79 %, achieved in the same quarter.
T2 Biosystems Inc 's Comment on Competition and Industry Peers
The company states that it is the only diagnostic firm with FDA-cleared or CE-marked commercial products capable of detecting sepsis-causing pathogens and antibiotic resistance genes directly from blood within three to five hours at low detection limits, without requiring a positive blood culture. Its main competitors are companies offering blood culture-dependent diagnostic platforms, which have greater market presence and financial resources. Traditional blood culture-based diagnostic providers include Becton Dickinson & Co. and bioMerieux, Inc. Additional competitors offering post-culture species identification through molecular and non-molecular methods include bioMerieux, Inc. (and its affiliate BioFire Diagnostics, Inc.), Bruker Corporation, Accelerate Diagnostics, Luminex, Roche, Cepheid, and Beckman Coulter (a Danaher company). These competitors depend on positive blood culture results, resulting in longer testing times compared to the company's technology. Some competitor products require significant hands-on labor or high pathogen concentrations in blood culture. New market entrants may be developing other post-blood culture diagnostic technologies. Karius, Inc. offers a lab-developed, culture-independent diagnostic test for pathogen identification that is not FDA-cleared but may be considered competitive.
December 17, 2024
T2 Biosystems Surpasses Key Milestone with 250,000 Sepsis Tests Shipped Globally Amid Financial Challenges In a significant achievement for T2 Biosystems Inc, the company has successfully shipped its 250,000th novel sepsis test globally, marking a crucial milestone in the adoption of its proprietary technology. This achievement reflects the growing global demand for T2 Biosystems advanced sepsis diagnostics, which promise to enhance patient outcomes through rapid and accurate detection of sepsis.The widespread acceptance of T2 Biosystems diagnostics is evident in the increasing number of healthcare providers who are incorporating these advanced tests into their clinical practice. This milestone underscores...
October 8, 2024
The ever-evolving landscape of antimicrobial resistance (AMR) presents an increasingly formidable challenge to public health worldwide. In response to this growing crisis, two cutting-edge biotechnology companies, T2 Biosystems, Inc. and Prxcision, Inc. have joined forces in a strategic co-marketing collaboration aimed at revolutionizing the field of diagnostics and antibiotic stewardship. This partnership exemplifies a proactive approach to curb the threat of AMR by integrating rapid diagnostic tools and AI-powered decision support systems. A Confluence of Innovation T2 Biosystems is renowned for its innovative diagnostic solutions, particularly its direct-from-blood diagnostic tools designed to rapidly det...
September 16, 2024
T2 Biosystems Receives FDA Clearance to Market T2Candida Panel for Pediatric Patients Amid Financial Challenges T2 Biosystems Inc. a prominent player in the field of innovative diagnostic solutions, has achieved a significant milestone. The company announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to market the T2Candida Panel for pediatric patients. This approval extends the availability of the T2Candida Panel, which is designed to detect sepsis-causing Candida infections directly from whole blood within 3-5 hours, now addressing a vulnerable patient population children. The development is particularly noteworthy, considering the potentially life-threatening nature of...
March 19, 2024
In a bid to tackle the rising concern of sepsis and antibiotic resistance, T2 Biosystems, Inc. (NASDAQ:TTOO) has made significant strides in rapid disease detection. With their latest announcement of the T2Lyme Panel launch plans and the FDA 510(k) clearance for the expanded T2Bacteria Panel, the company is set to transform the landscape of disease diagnostics. This article delves into the implications of these developments and their potential impact on healthcare systems and patient outcomes.The T2Lyme Panel Unveiling:T2 Biosystems management has scheduled an investor call on March 20, 2024, to unveil the T2Lyme Panel launch plans and provide critical business updates. As a leader in the rapid detection of...
February 15, 2024
T2 Biosystems Expands its Presence in Europe and Asia through Distribution PartnershipsLEXINGTON, Mass., Feb. 15, 2024 - T2 Biosystems, a renowned leader in rapid pathogen and antibiotic resistance detection for sepsis, announced today its strategic move towards commercial expansion in Europe and Asia. The company has successfully executed exclusive distribution agreements for new geographical areas, including the Netherlands, Belgium, Vietnam, and a re-entry into Switzerland. These partnerships will allow T2 Biosystems to introduce their innovative products, including the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, and the T2Resistance Panel, to healthcare professionals and patients in these...
February 12, 2024
In a significant move towards revolutionizing the field of diagnostics, T2 Biosystems recently announced receiving FDA 510(k) clearance for the expanded T2Bacteria Panel. This ground-breaking development in microbial detection aims to combat the growing menace of healthcare-associated infections (HAIs) by significantly increasing the number of bacteria species detected. Notably, the addition of Acinetobacter baumannii further strengthens the panel s efficacy.With HAIs remaining a persistent challenge in healthcare settings, the need for improved diagnostics that can accurately identify the causative agents cannot be emphasized enough. In this context, T2 Biosystems has played a pivotal role by spearheading t...
Co Diagnostics Inc is a biotech company that follows a business-to-business (B2B) model. They develop and manufacture molecular diagnostics for various infectious diseases. Their revenue is generated by selling these diagnostics directly to healthcare organizations, laboratories, and research institutions.
Accelerate Diagnostics Inc operates under a business model that focuses on developing and commercializing innovative solutions for the rapid identification and antimicrobial susceptibility testing of infectious pathogens. Their products offer healthcare facilities a more efficient and accurate approach to diagnosing and treating infections, ultimately improving patient outcomes.
Navidea Biopharmaceuticals Inc's business model revolves around the development and commercialization of innovative precision medicines and diagnostic tests. They focus on targeting specific diseases to provide more accurate diagnostics and targeted therapies.
Rapid Therapeutic Science Laboratories Inc is a biotechnology company that focuses on developing and manufacturing pharmaceutical and nutraceutical products. Their business model revolves around conducting research and development to create innovative solutions, manufacturing products at their own facilities, and marketing and distributing these products through various channels to reach customers worldwide. They aim to provide safe and effective solutions for a range of health and wellness needs.
Sources:
T2 Biosystems Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on T2 Biosystems Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
